Loading...
Market
What will be the competitive response to CN201 by August 9, 2025?
2
Resolution / Starting Odds
New competing drug approved • 25%
Price reduction in similar drugs • 25%
Increased marketing for existing drugs • 25%
No significant response • 25%
Official announcements from competing pharmaceutical companies
Story
Merck Acquires CN201 B-Cell Therapy for Up to $1.3 Billion
Aug 9, 2024, 12:11 PM
Merck has announced its acquisition of CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical. CN201 is a next-generation CD3xCD19 bispecific antibody that aims to enhance and diversify Merck's pipeline. The drug has potential applications in treating B-cell malignancies and autoimmune diseases. The deal is valued at up to $1.3 billion, reflecting Merck's continued investment in innovative therapies.
View original story
Similar markets
Apple • 25%
Microsoft • 25%
Amazon • 25%
No Major Response • 25%
Fully operational • 25%
Partially operational • 25%
Still halted • 25%
Other • 25%
Publicly supportive • 25%
Publicly opposed • 25%
No public comment • 25%
Mixed reactions • 25%
Condemnation • 25%
Support • 25%
Neutral • 25%
No response • 25%
Cybersecurity enhancements • 25%
Diplomatic measures • 25%
Economic sanctions • 25%
Military posturing • 25%
Tariffs on US goods • 25%
Restrictions on US tech companies • 25%
Investment in domestic semiconductor industry • 25%
No significant countermeasures • 25%
New labor agreement • 25%
Government intervention • 25%
Prolonged shutdown • 25%
Other • 25%
New competing product released • 33%
Existing product significantly updated • 33%
No significant response • 33%
Google • 25%
Microsoft • 25%
Amazon • 25%
Other • 25%